This industry comprises establishments primarily engaged in encompasses a wide range of activities related to the study and application of genomes—the complete set of DNA within an organism. This industry integrates various scientific disciplines, technologies, and commercial applications to understand, manipulate, and utilize genetic information for multiple purposes.
Minerva has clients in this industry in North America, and across the globe.
United States, 2022
| Research and Development in Biotechnology (except Nanobiotechnology) (NAICS 541714) | |
|---|---|
| Employer establishments | 5,329 |
| Paid employees | 153,771 |
| Annual payroll | US$29.84 billion |
| Average payroll per employee | US$194,064 |
Canada, July 2023
| Research and development in the physical, engineering and life sciences (NAICS 541710) | |
|---|---|
| Business locations with employees | 2,696 |
| Share with 1–99 employees | 94.3% |
U.S. figures count employer establishments (physical locations); Canadian figures count business locations with employees. The two measures are not directly comparable. No genomics-specific code. US 541714 covers biotech R&D (broader than genomics). Canada 541710 covers all physical/engineering/life sciences R&D (much broader). Treat as proxy only.
$1 Million - $5 Million Net Sales
Statistics (Genomics)
Genomics companies are often valued before they are profitable, so their intellectual property and funding position are central. Progress toward clinical or regulatory milestones and strategic partnerships can change value significantly.
Sources
Minerva's CBVs value genomics companies for family law matters, tax and estate planning, and transactions.